Mitochondrial-Targeting Anticancer Agent Conjugates and Nanocarrier Systems for Cancer Treatment

Area of Science:

• Biochemistry
• Cell Biology
• Pharmacology

Background:

• Mitochondria play crucial roles in cellular proliferation and death, making them attractive targets for drug development.
• Mitochondrial targeting has gained prominence over nuclear targeting due to unique cellular functions.
• The higher mitochondrial membrane potential in cancer cells facilitates selective drug accumulation.

Purpose of the Study:

• To review mitochondria-targeting ligand-conjugated anticancer agents and their therapeutic potential.
• To discuss mitochondria-targeted nanocarrier systems for enhanced anticancer drug delivery.
• To explore strategies for optimizing mitochondria-targeted agent development.

Main Methods:

• Literature review of studies on mitochondria-targeting anticancer agents.
• Analysis of *in vitro* and *in vivo* data for conjugated drugs and nanocarrier systems.
• Discussion of ligand selection and linker strategies for targeted drug development.

Main Results:

• Mitochondria-targeting agents show promise but often require further optimization for direct cancer therapy.
• Conjugation of targeting ligands to therapeutic agents can improve efficacy.
• Nanocarrier systems offer solutions for solubility and selectivity challenges in mitochondria-targeted drug delivery.

Conclusions:

• Mitochondria-targeted drug conjugates and nanocarrier systems represent a promising strategy for advancing cancer therapy.
• Further research into optimal ligand-linker design and nanocarrier formulation is crucial.
• Selective targeting of mitochondria holds significant potential for developing more effective anticancer treatments.